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Divergent T-cell receptor recognition modes of a
HLA-I restricted extended tumour-associated
peptide
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Jonathan Cebon1, James McCluskey 2, Weisan Chen 1,4 & Jamie Rossjohn 3,5,6
Human leukocyte antigen (HLA)-I molecules generally bind short peptides (8–10 amino acids),
although extended HLA-I restricted peptides (>10 amino acids) can be presented to T cells.
However, the function of such extended HLA-I epitopes in tumour immunity, and how they
would be recognised by T-cell receptors (TCR) remains unclear. Here we show that the
structures of two distinct TCRs (TRAV4+TRAJ21+-TRBV28+TRBJ2-3+ and TRAV4+TRAJ8
+-TRBV9+TRBJ2-1+), originating from a polyclonal T-cell repertoire, bind to HLA-B*07:02,
presenting a 13-amino-acid-long tumour-associated peptide, NY-ESO-160–72. Comparison of the
structures reveals that the two TCRs differentially binds NY-ESO-160–72–HLA-B*07:02 complex,
and induces differing extent of conformational change of the NY-ESO-160–72 epitope. Accord-
ingly, polyclonal TCR usage towards an extended HLA-I restricted tumour epitope translates to
differing TCR recognition modes, whereby extensive ﬂexibility at the TCR–pHLA-I interface
engenders recognition.
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Human leukocyte antigen (HLA)-I molecules are of centralimportance in the presentation of antigenic peptides,enabling CD8+ T cells to eliminate cancerous and virally
infected cells. Typically, HLA-I molecules present peptides
between 8 and 10 amino acids in length1, where the N- and C-
termini of the peptide are ﬁxed within the P2 and PΩ binding
pockets of the antigen (Ag)-binding cleft, respectively. However,
HLA-I molecules can present extended peptides (>10 amino
acids), whereby the N- and C-termini are similarly constrained
within the HLA-I molecule, forcing the central region of the
peptide to bulge from the Ag-binding cleft2. In addition, the
HLA-associated peptide repertoire may be further expanded via
N-terminal extensions on presented peptides, as observed for
HLA-B*57:013. C-terminal protrusions have also been observed4
and were shown to extend out of the F pocket of the HLA-I
binding groove5. Collectively, it has been estimated that extended
peptides could comprise as much as 10% of the total HLA-I
peptide repertoire6–10. Accordingly, it is difﬁcult to predict a
priori how extended peptides will be accommodated within the
HLA-I molecule, and subsequently recognised by the T-cell
receptor (TCR)6,8,11. Nevertheless, a number of studies have
reported the importance of extended peptides in CD8+ T-cell-
mediated immunity—mostly in the axis of viral immunity6,12–17.
Extended peptides presented by HLA-I molecules can adopt
highly dynamic conformations, thereby presenting differing
energetic barriers for TCR ligation1,18. Extended peptides are
generally considered to be challenging targets for TCR recogni-
tion owing to the dynamic nature of the central bulge19–25, in
contrast to peptides of canonical length26–28. Extended peptides
were frequently associated with highly biased T-cell reper-
toires1,7,9,10,18,29, thought to be resultant from conserved and
HLA-I-centric TCR docking topologies12–15,18,20,30. Notwith-
standing recent exceptions31,32, the majority of TCR–pHLA-I
structural data available exhibits a ﬁxed polarity, whereby the
TCR α- and β-chains are positioned over the HLA-I α2 and α1-
helices, respectively1, although how this is related to extended
epitopes remained unclear. Relatively little is known regarding
TCR engagement of extended peptides despite their apparent
importance in tumour immunosurveillance6,33, with extended
epitopes identiﬁed for the tumorigenic antigens CAMEL34,
MAGE-A135,36, and NY-ESO-117. Presently, TCR recognition of
extended epitopes has demonstrated starkly contrasting docking
mechanisms. For example, one TCR docked atop the super-
bulged LPEP (BZLF152-64) peptide, making limited contact with
the HLA-I molecule itself12. A subsequent study described how
another TCR docked towards the N-terminal end of this bulged
peptide, making more extensive contacts with the HLA-I
although the peptide conformation remained unchanged16.
Conversely, another crystal structure described TCR recognition
of an 11-amino-acid peptide, where the TCR ﬂattened the bulged
peptide upon ligation13.
NY-ESO-1 is an immunogenic cancer-testis antigen that is
spontaneously expressed on a range of melanomas and other
cancers including myelomas17,37. A key mediator of NY-ESO-1
immunity is CD8+ T cells with observations of CD8+ T-cell
inﬁltration correlating with NY-ESO-1 expression and inversely
correlating with tumour progression in vivo38. NY-ESO-1
restricted T cells therefore are of great interest due to their
potential use for targeted immunotherapeutic treatment of
tumours. Indeed, NY-ESO-1-speciﬁc engineered T cells have been
studied for therapeutic use in multiple myeloma treatment39.
Here T cells raised against NY-ESO-1157–165 presented by HLA-
A*02:01 were clonotyped40, structurally characterised41, and used
for phage display to generate TCRs with picomolar afﬁnity for the
NY-ESO-1157–165 antigen42. The engineered T cell then formed
the framework (FW) for engineered T-cell therapy, with the NY-
ESO-1 restricted T cells showing targeted antitumour activity in
clinical trials39.
In addition to the HLA-A*02:01-directed response, an immu-
nodominant extended peptide was identiﬁed, which was pre-
sented by HLA-B*07:0217. To identify the principles
underpinning extended peptide recognition, here we investigated
TCR binding of an immunodominant NY-ESO-1 13-amino-acid
peptide (APRGPHGGAASGL) derived from positions 60–72 of
the cancer-testis antigen, NY-ESO-1. We examined the HLA-
B*07:02-NY-ESO-1 restricted CD8+ T-cell repertoire, previously
shown to exhibit a diverse TRBV gene repertoire in vaccinated
HLA-B*07:02+ melanoma patients17. Further, we isolated and
characterised four individual T-cell clones that were representa-
tive of the many TRBV families. The binding of two distinct
TCRs to NY-ESO-160–72-HLA-B*07:02 was via either ﬂattening or
stabilisation of the extended peptide. This represents the ﬁrst
example of how a HLA-restricted peptide adopts markedly dif-
fering conformations upon engaging differing TCRs, thereby
providing key insights into TCR recognition of extended peptides
in the context of polyclonal TCR recognition.
Results
NY-ESO-160–72-HLA-B*07:02-speciﬁc CD8+ T-cell clonotypes.
To investigate the basis of extended peptide reactivity by poly-
clonal T cells from diverse TRBV families, we isolated and
expanded NY-ESO-160–72-HLA-B*07:02 reactive CD8+ T cells
from peripheral blood mononuclear cells (PBMC) of patients
with melanomas expressing NY-ESO-1. Following vaccination
with NY-ESO-1 protein formulated with ISCOMATRIXTM
adjuvant43, an expansion of CD8+ T cells were observed at day
71, and persisted to day 197 post vaccination following in vitro
stimulation with NY-ESO-1(55–72) peptide. Intracellular cyto-
kine staining (ICS) measuring interferon-γ (IFN-γ) production
was used to identify and enumerate the NY-ESO-1(55–72)-HLA-
B*07:02 reactive cells within this expanded CD8+ T-cell pool
(Fig. 1a). Previous peptide screening studies identiﬁed NY-ESO-
160–72 as the active 13-amino-acid epitope17. Thus, T cell speci-
ﬁcity for NY-ESO-160–72-HLA-B*07:02 in the expanded CD8+ T-
cell pool was determined by tetramer staining. A similar trend in
NY-ESO-160–72-HLA-B*07:02 tetramer-positive T cells was seen
post vaccination as for IFN-γ production within the T-cell pool
(Fig. 1b). Further, CD3+ CD8+ NY-ESO-160–72-HLA-B*07:02
tetramer-positive T cells were single cell sorted and expanded.
TRBV gene usage of the T-cell clones was determined using a
panel of Vβ speciﬁc antibodies (Supplementary Fig. 1a) and in-
depth analysis of the paired α- and β-chain TCR gene usage of the
sorted cells was done using TCR gene sequencing. To determine
the paired α- and β-chain TCR gene usage of the isolated cells,
TCR gene sequencing on four selected clones was performed
(Table 1). Notably, no consensus motif/TCR bias was evident
within the NY-ESO-160–72-HLA-B*07:02-reactive TCR sequences
in contrast to TCRs previously shown to recognise other extended
peptides12–16.
Characterisation of NY-ESO-160–72-HLA-B*07:02 reactivity. To
conﬁrm the NY-ESO-160–72 reactivity of the HLA-B*07:02-
restricted CD8+ T-cell clones, we selected four clones, all of
which bound the NY-ESO-160–72-HLA-B*07:02 tetramer
(Fig. 1c). The clones represented a cross-section of the TCRα and
TCRβ gene usage. These clones, KFJ4 (TRAV13-1+TRAJ37+ or
TRAV26-1+TRAJ50+, TRBV10-3+ TRBD1+ TRBJ1-2+), KFJ5
(TRAV4+TRAJ21+, TRBV28+TRBD1+TRBJ2-3+), KFJ15
(TRAV17+TRAJ20+, TRBV6-1+ TRBD1+ TRBJ2-7+), and
KFJ37 (TRAV4+TRAJ8+, TRBV9+TRBD1+ TRBJ2-1+), and
suitable controls (the HLA-B*08:01-restricted TCR, LC1344) were
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used to generate a panel of TCR-transduced SKW3 T-cell lines.
With the exception of the TRAV26-1+ KFJ4-SKW3 cells, these
TCR-SKW3 cell lines up-regulated the T-cell activation marker
CD69 upon stimulation with NY-ESO-160–72 peptide-pulsed
HLA-B*07:02+ antigen-presenting cells (APCs) (Fig. 1d). The
KFJ4 T-cell clone carried two productive rearrangements of the
TCR Vα-domain (Table 1) as identiﬁed in ~30% of T cells45, yet
only the TRAV13-1+ TRAJ37+ α-chain (paired with TRBV10-3+
TRBD1+ TRBJ1-2+ Vβ-chain) formed a functional NY-ESO-
160–72-HLA-B*07:02 restricted TCR (Fig. 1d). The four functional
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Fig. 1 Functional reactivity of CD8+ T cells binding to HLA-B*07:02 presenting NY-ESO-160–72. a Flow cytometry analysis of melanoma patient’s PBMCs
showing CD8+ T-cell expansion pre- (Day 0) and post- (Days 71 and 197) NY-ESO-1-ISCOMATRIXTM vaccination following in vitro stimulation with NY-
ESO-1(55–72) peptide as assayed by intracellular cytokine staining (ICS) measuring interferon-γ (IFN-γ) production. b Flow cytometry analysis showing a
distinct NY-ESO-160–72-HLA-B*07:02 reactive CD8+ T-cell population following vaccination and in vitro stimulation with NY-ESO-1(55–72) peptide. Four
functionally distinct NY-ESO-160–72-HLA-B*07:02-speciﬁc CD8+ T-cell clones were identiﬁed from the melanoma patient’s PBMCs. c NY-ESO-160–72-HLA-
B*07:02 tetramer-positive CD8+ T-cell clones were generated from single-cell cloning. d Four NY-ESO-160–72-HLA-B*07:02-speciﬁc TCRs were retrovirally
reconstituted in SKW3 cells and recognised NY-ESO-160–72-HLA-B*07:02 presented on peptide-pulsed HLA-B*07:02+ antigen-presenting cells (APCs).
The overlaid ﬂow cytometry histograms of CD69 up-regulation in TCR-transduced SKW3 cells following co-incubation with NY-ESO-160–72 peptide-pulsed
(blue histogram) or non-pulsed APCs (red histogram). The SKW3 subsets were gated on live lymphocytes, CD3hi GFPhi markers and were subsequently
displayed as % of max (Y-axis) versus CD69 (X-axis). LC13 TCR-transduced SKW3 cells served as a TCR positive but nonreactive control as we have
shown it recognises the EBNA-3A339–347 peptide-pulsed HLA-B*08:01+ APCs and up-regulated CD69 surface marker44. A second independent retroviral
transduction experiment was performed for the KFJ4 (TRAV13), KFJ4 (TRAV26), KFJ37 and LC13 TCRs, with consistent results, see Supplementary Fig. 4.
e Four different NY-ESO-160–72-HLA-B*07:02-speciﬁc T-cell clones were individually co-incubated with HLA-B*07:02+ and NY-ESO-1-expressing SK-Mel-
14 cells in 1:2 ratio in the presence of 10 μg mL−1 of Brefeldin A for 5 h to detect naturally presented NY-ESO-160–72-HLA-B*07:02. CD8+ T-cell clone
recognition of naturally presented NY-ESO-160–72-HLA-B*07:02 on NY-ESO-1-expressing melanoma cell line, SK-Mel-14. CD8+ T-cell responses were
assayed by ICS measuring IFN-γ production. f Functional sensitivity of the CD8+ T-cell clones to exogenous NY-ESO-160–72 peptide at different
concentrations. CD8+ T-cell clones that are sensitive to lower levels of antigen are considered to possess high avidity
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03321-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1026  | DOI: 10.1038/s41467-018-03321-w |www.nature.com/naturecommunications 3
CD8+ T-cell clones were conﬁrmed to recognise naturally pre-
sented NY-ESO-160–72-HLA-B*07:02 on the surface of SK-Mel-14
melanoma cells, as measured by induction of IFN-γ production
(Fig. 1e). We then compared the functional reactivity of the TCR
clones upon titrated NY-ESO-160–72 peptide-pulsed APC stimu-
lation. All four TCRs induced IFN-γ production at very low
peptide concentrations (≤10−9 M) (Fig. 1f). Interestingly, the
KFJ15 clone elicited a lower avidity response, consistent with the
reduced level of staining (Fig. 1e) and faster dissociation (Sup-
plementary Fig. 1b) of the NY-ESO-160–72-HLA-B*07:02
tetramer.
To characterise the ﬁne speciﬁcity of the identiﬁed T-cell
clones speciﬁc to the NY-ESO-160–72-HLA-B*07:02 complex on
T-cell reactivity, we conducted an alanine-scanning assay. Here,
the four T-cell clones displayed reduced reactivity to centrally
mutated peptides (P4-Gly→P8-Gly), indicating the importance of
the central region of the NY-ESO-160–72 peptide (Fig. 2a and
Supplementary Fig. 2) in TCR recognition17. Interestingly, the
tolerance of KFJ5 and KFJ37 T-cell clones towards the P3-Arg
mutation differed, with KFJ37 retaining ~90% of reactivity,
whereas KFJ5 reactivity was completely ablated (Fig. 2a and
Supplementary Fig. 2), suggesting that the KFJ5 and KFJ37 TCRs
focused on the central region of the NY-ESO-160–72 peptide
presented by HLA-B*07:02 with differing ﬁne speciﬁcities. We
then examined the CD8 dependency of these TCRs, with each
T-cell clone showing reduced activation when stimulated by NY-
ESO-160–72 peptide in the presence of a blocking CD8 antibody.
This effect was most pronounced at low peptide concentrations
(Supplementary Fig. 3) and served to highlight the importance of
CD8 in NY-ESO-160–72-HLA-B*07:02 restricted T-cell activation.
CD8+ T-cell clones with higher avidity for NY-ESO-160–72-HLA-
B*07:02 tetramer (Supplementary Fig. 1) correlated well with
their activation by lower peptide concentration (Fig. 1f) and by
melanoma cells (Fig. 1e). Thus, ﬁne speciﬁcity analysis indicated
that the four TCRs exhibited different modes of interaction
within the common central region of the NY-ESO-160–72 epitope.
Afﬁnities for the NY-ESO-160–72–HLA-B*07:02 complex. We
next determined the afﬁnity of the four TCRs towards the NY-
ESO-160–72–HLA-B*07:02 complex using surface plasmon reso-
nance (SPR). Soluble ectodomains of the KFJ4, KFJ5, KFJ15 and
KFJ37 TCRs, as well as the NY-ESO-160–72–HLA-B*07:02 com-
plex were expressed, refolded and puriﬁed17,46. As expected, the
KFJ4, KFJ5, KFJ15 and KFJ37 TCRs did not bind to the control
pHLA complex. The KFJ4, KFJ15 and KFJ37 TCRs bound to NY-
ESO-160–72-HLA-B*07:02 with an afﬁnity (KD) of 40–50 μM
(Fig. 2b, c). In contrast, the KFJ5 TCR bound with a markedly
reduced afﬁnity of >200 µM, suggesting greater structural chal-
lenges to TCR binding14–16,20. We next investigated the binding
kinetics by determining the on-rate (kon), which were only
measurable for the KFJ4 and KFJ37 TCRs. These values appeared
notably slow when comparing the SPR sensorgrams and equili-
brium binding curves (Fig. 2b, c) to other TCR-binding studies14–
16,20,47. Similarly, the SPR sensorgrams for the KFJ5 and KFJ15
TCRs show a similarly pronounced slow association rate. The
slow on-rates of these TCRs further suggest that TCR or peptide
conformational rearrangements may be required for NY-ESO-
160–72 recognition, in contrast to TCR recognition of the rigid
super-bulged LPEP peptide presented by HLA-B*35:0816,20.
The NY-ESO-160–72 peptide adopts a bulged conformation. To
evaluate presentation of the NY-ESO-160–72 peptide by HLA-
B*07:02, we determined the structure of HLA-B*07:02 presenting
the NY-ESO-160–72 peptide to a resolution of 1.5 Å, which was
signiﬁcantly higher than the 2.1 Å resolution structure reported
previously17 (Table 2). Superimposition of the HLA-B*07:02
molecule onto the structure of HLA-B*07:02 bound to a nona-
meric RFL9 peptide48 illustrated little movement in the HLA-I
molecule (root-mean-squared deviation (r.m.s.d.) of 0.2 Å)
(Fig. 2e), despite presenting distinct peptides. Given the anchored
restraints at the peptide extremities, the central residues,
encompassing P4-Gly→P11-Ser of the NY-ESO-160–72 peptide,
bulged extensively out of the peptide-binding groove. Here, the
solvent accessible surface area of the NY-ESO-160–72 peptide was
double that of the RFL9 peptide (620 Å2 compared to 290 Å2),
thereby providing an extended surface for TCR-mediated recog-
nition. Notably, although solved to high resolution, P6-His-P8-
Gly side chains were not clearly observed in the electron density
(Fig. 2d), which suggested conformational plasticity in this region
of the peptide.
Overview of TCR-NY-ESO-160–72–HLA-B*07:02 complexes.
Next, we determined the structure of the KFJ5 and KFJ37 TCRs
complexed to NY-ESO-160–72-HLA-B*07:02 (Table 2). The well-
deﬁned electron density at the respective TCR-NY-ESO-
160–72–HLA-B*07:02 interfaces enabled the ternary complexes
to be readily reﬁned and interpreted. The KFJ37 TCR and KFJ5
TCR adopted similar and canonical docking modes, binding
centrally atop the pHLA-I (Fig. 3a, b), with a docking angle of
approximately 70° across the peptide-binding groove of HLA-
B*07:02, whereby the Vα and Vβ of the TCR positioned over the
α2- and α1-helices, respectively (Fig. 3d, e). In comparison to the
KFJ37 TCR ternary complex, the KFJ5 TCR was shifted by ~2.5 Å
towards the α1-helix, resulting in the Vα chain docking more
centrally above the peptide-binding groove and the Vβ chain
positioning more peripherally (Fig. 3e). The docking modes
observed here differed notably from the SB27 TCR recognition of
the LPEP–HLA-B*35:08 complex (Fig. 3c). Here, the SB27 TCR
adopted a 90° docking angle and bound towards the N-terminus
Table 1 NY-ESO-160–72-HLA-B*07:02-speciﬁc αβ TCR sequences
CD8+
T-cell clone
TCR-α chain TCR-β chain
TRAV TRAJ CDR1α CDR2α CDR3α TRBV TRBD TRBJ TRBC CDR1β CDR2β CDR3β
KFJ4 13-1*02 37*01 DSASNY IRSNVGE CAASLNTGKLIF 10-3*02 1*01 1-2*01 1 ENHRY SYGVKD CAILGQGYGYTF
26-1*01 50*01 TISGNEY GLKNN CIVRGETSYDKVIF
KFJ5 4*01 21*01 NIATNDY GYKTK CLVGEILDNFNKFYF 28*01 1*01 2-3*01 2 MDHEN SYDVKM CASSQRQEGDTQYF
KFJ15 17*01 20*01 TSINN IRSNERE CATGNDYKLSF 6-1*01 1*01 2-7*01 2 MNHNS SASEGT CASQTFSPGQTQF
KFJ37 4*01 8*01 NIATNDY GYKTK CLVVDQKLVF 9*01 1*01 2-1*01 2 SGDLS YYNGEE CASSGGHTGSNEQFF
Non-germline encoded residues for the respective CDR3 regions are highlighted in bold italics
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Fig. 2 NY-ESO-160–72 peptide speciﬁcities and steady-state afﬁnities for CD8+ T-cell clones. a Normalised data for IFN-γ production by different
CD8+ T-cell clones when stimulated with 10−7 M concentration of native NY-ESO-160–72 peptide (APRGPHGGAASGL) or single alanine-substituted
peptides. CD8+ T cell responses stimulated by native peptide for each clones were accorded as 100%, and other CD8+ T cell responses stimulated by
single alanine-substituted peptides were calculated as a relative percentage to the native peptide responses. CD8+ T cell responses stimulated by different
single alanine-substituted peptides concentrations are shown in Supplementary Fig. 2. Surface plasmon resonance sensorgrams (b) and equilibrium binding
curves (c) showed that the in vitro refolded and puriﬁed recombinant TCRs (immobilised at ~300–350 response units) interacted with NY-ESO-160–72-
HLA-B*07:02 (screened at serial dilutions from 200 to 0 µM). SPR sensorgrams are representative of a single experiment. Equilibrium binding curves were
derived from two replicate experiments with KD, kon, koff and equilibrium curve means calculated from the duplicate experiments (error and error bars
denote SEM). d The observed electron density (2mFo-DFc), shown as blue mesh, for the NY-ESO-160–72 peptide contoured to 1σ illustrates the structural
plasticity and ﬂexibility of the central peptide residues (P6-His-P8-Gly). e NY-ESO-160–72 adopts a bulged conformation upon presentation by HLA-
B*07:02. Comparison of the NY-ESO-160–72-HLA-B*07:02 bulged peptide presentation with the RL9-HLA-B*07:02 peptide presented in a canonical fashion
(PDB: 5EO1). The heavy chain is shown in grey with the NY-ESO-160–72 and RL9 peptides shown in black and red, respectively
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of the LPEP peptide and made limited contacts with the HLA-I
molecule (Fig. 3f, i)16.
The total buried surface area (BSA) of the KFJ37 TCR-NY-
ESO-160–72–HLA-B*07:02 interface was 2350 Å2, of which the
TCR α- and β-chains contributed approximately equally (45%
and 55%, respectively) (Fig. 3g). The KFJ37 TCR NY-ESO-
160–72–HLA-B*07:02 interface comprised residues from both
germline and non-germline residues with each CDR loop of the
α-chain (20%, 7%, 15% and 1% BSA from the CDR1α, CDR2α,
CDR3α and FW, respectively) and β-chain (2%, 18%, 26% and
9% BSA from the CDR1β, CDR2β, CDR3β and FW, respectively)
contributing to HLA-B*07:02 recognition (Fig. 3g). Here, Asn31α
and Tyr33α (CDR1α) projected down towards the HLA-I surface
and formed hydrogen bonds to Arg62 and Trp167, and Ala158,
Tyr159 and Glu163 of the HLA-I, respectively (Fig. 4a and
Supplementary Table 1). The CDR1α contacts to the HLA-I
surface were further stabilised via extensive van der Waals
contacts involving Asn31α and Tyr33α, in addition to Thr30α
contacting Glu163, Glu166, Trp167 of the HLA-I α2-helix.
Further, Lys58α (CDR2α) formed a hydrogen bond to Glu161 of
the HLA-I α2-helix. Additionally, Asp108α (CDR3α) formed a
salt bridge with Arg62 of the α1-helix (Fig. 4a and Supplementary
Table 1). The β-chain of the KFJ37 TCR makes further ionic
interactions with the HLA-I α1-helix, whereby Glu59β (CDR2β)
salt bridged to the protruding Arg78 (Fig. 4b and Supplementary
Table 1). This interaction surface was further stabilised via
hydrogen bonds from Glu60β (CDR2β) and Arg66β (FWβ) to the
neighbouring residue on the α1-helix, Gln75 (Fig. 4b and
Supplementary Table 1).
The total BSA of the KFJ5 TCR-NY-ESO-160–72–HLA-B*07:02
interface was notably smaller at 1560 Å2. Here, the KFJ5 TCR
ternary interface was dominated by TCR α-chain contacts, which
contributed ~75% of the BSA. The CDR1α, CDR2α, CDR3α and
FWα loops contributed 30%, 4%, 38% and 2%, respectively, to the
BSA of the interface, whereas only the CDR3β of the β-chain
contributed (25% BSA) to the interface (Fig. 3h and Supplemen-
tary Table 2). The KFJ5 β-chain formed limited contacts with the
HLA-I surface and comprised contacts only from the CDR3β
loop, including Arg109β, which contacted Thr73 and the main
chain of Ala69 of the α1-helix, and Gln110β, which contacted
Glu152 of the α2-helix (Fig. 4e and Supplementary Table 2). In
the KFJ5 TCR ternary complex, contact to the HLA-I surface was
facilitated via an extension of the F-strand of the KFJ5 Vα domain
over the N-terminal extremity of the α1-helix (Fig. 4d). Here the
CDR3α loop is distended through the incorporation of four
additional amino acids whereby the non-germline residues served
to cap the peptide-binding groove of the HLA-I along with the
germline Asn112α (CDR3α), which formed a hydrogen bond with
Gln65 of the α1-helix (Fig. 4d and Supplementary Table 2). Given
the commonality of the TRAV4*01 chains between the KFJ37 and
KFJ5 TCRs, it was of interest that there were some conserved
TRAV4*01-mediated contacts. Namely, Thr30α of the CDR1α
made conserved van der Waals contacts to Gln163, Glu166 and
Trp167 (Fig. 5f). Further, the neighbouring Asn31α made a
conserved hydrogen bond to Trp167 and contacts with Arg62
(Fig. 5f). Interestingly, Tyr33α made conserved van der Waals
contact to Glu163, as well as conserved coordination of P6-His
(Fig. 4c, f), In addition, the TRAV4*01-encoded Thr30α and
Gln55α made conserved contacts to the P6-His of the peptide
(Fig. 5f). Further, non-germline commonalities included a salt-
bridge contact from Asp/Glu108α to Arg62 of the HLA-B*07:02 α1-
helix (Fig. 5f). Thus, while the KFJ37 and KFJ5 TCRs share the same
TRAV-encoded region and adopt a similar positioning atop the
pHLA-I, the extent and details within the respective interfaces
differ markedly, despite recognising the same HLA–peptide
complex.
Differential TCR recognition of the NY-ESO-160–72 peptide.
The position of the KFJ37 TCR CDR loops on the HLA-
B*07:02 surface allows the TCR to completely encapsulate the
protruding NY-ESO-160–72 peptide (Fig. 4c). Indeed, the central
part of the peptide was sandwiched between both CDR3 loops
and three-tyrosine residues from CDR1α, FWβ and CDR2β
(Supplementary Table 1). As observed in the binary structure, the
central portion of the NY-ESO-160–72 peptide arched out of the
peptide-binding groove, yet here was stabilised upon KFJ37 TCR
ligation (Fig. 4c). Namely, the central region (P6-His→P9-Ala) of
the NY-ESO-160–72 peptide formed extensive contacts with the
KFJ37 TCR. Here, P6-His made hydrogen bonding contacts with
Tyr33α of the CDR1α loop and Gln55α of the FWα (Fig. 4c and
Supplementary Table 1) and also made a water-mediated contact
to Ser113β of the CDR3β. The bulging peptide was further sta-
bilised by Ser107β and Ser113β of the CDR3β loop, which formed
hydrogen bonds to the peptide main chain at positions P9-Ala,
and P8-Gly, respectively, in addition to numerous van der Waals
contacts to the peptide (Fig. 4c and Supplementary Table 1).
Indeed, the bulging peptide comprised 36% of the interaction
surface (BSA) for KFJ37 TCR-mediated HLA-B*07:02 recogni-
tion, comparable to the ~41% contribution to peptide-mediated
recognition in SB27 TCR12.
In stark contrast, the NY-ESO-160–72 peptide underwent
dramatic remodelling upon recognition by the KFJ5 TCR, due
in part to the steric occlusion from the distended CDR3α loop
and the coordination of the CDR3β loop. Here, the super-bulged
NY-ESO-160–72 topology was deformed upon KFJ5 TCR ligation
and adopted a ‘helical’ peptide conformation (P5-P8) (Fig. 4f), the
impact of which resulted in a relatively ﬂattened epitope upon
KFJ5 TCR engagement, which in turn resulted in a markedly
reduced (~20%) contribution to the interaction surface. Peptide
recognition in the KFJ5 TCR ternary complex was almost entirely
modulated via van der Waals interactions, notwithstanding the
solitary hydrogen bond to the peptide from Asp113β of the
CDR3β to P6-His, which ﬂipped 180° into an upright conforma-
tion, compared to the KFJ37 TCR complex, while retaining
contacts with Tyr33α of the CDR1α (Fig. 4f and Supplementary
Table 1). The large deformation of the bulged peptide is
coordinated via water-mediated interactions from the KFJ5
TCR CDR3 loops with Glu108α and Gln110β serving to stabilise
the helical peptide main chain at P6-His and P5-Pro, respectively
(Fig. 4f and Supplementary Table 2). Van der Waals interactions
included Glu108α, Ile109α and Leu110α of the CDR3α, to P4-Gly
and P5-Pro of the peptide, which further contributed to the
peptide interface with the α-chain of the KFJ5 TCR (Fig. 4f and
Supplementary Table 2). Conversely, the β-chain made limited
contribution to the TCR–peptide interface, with only Arg109β
and Gln110β of the CDR3β loop making van der Waals contacts
with P10-Ala and P11-Ser peptide side chains (Supplementary
Table 2).
Superimposition of the two-peptide conformations revealed an
r.m.s.d. value of 3.6 Å over the 81 atoms of the peptide,
representing a considerable remodelling (Fig. 5a–d). While the
N-terminus of the NY-ESO-160–72 peptides remained unchanged
from P1-Ala→P5-Pro (Fig. 5a–d), the coordination chemistry of
the peptide backbone shifted drastically through positions P6-His,
P7-Gly, P8-Gly and P9-Ala with the α-carbon of each residue
moving 3.1, 9.7, 9.6 and 7.2 Å, respectively (Fig. 5e). Taken
together, these structures indicated that the NY-ESO-160–72
peptide was highly malleable prior to engagement by two cognate
TCRs.
Peptide plasticity is complemented by TCR malleability. To
further understand the remodelling at the TCR-NY-ESO-
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160–72–HLA-B*07:02 interface, we determined the structure of the
KFJ5 TCR in an unligated form (Table 2). When comparing the
KFJ5 TCR in a ligated and unligated form (Supplementary
Fig. 5a), the CDR regions underwent signiﬁcant remodelling. A
large movement of the CDR3α was observed in which residues
Glu108α to Phe116α (Supplementary Fig. 5b & d) moved ~9 Å
upon recognition of the NY-ESO-160–72–HLA-B*07:02 complex.
A more modest remodelling was observed within the CDR
regions of the β-chain, whereby the CDR3β displayed the largest
shift of ~2 Å upon ligation (Supplementary Fig. 5c & d). The
pronounced movement of the KFJ5 TCR CDR3α loop is indeed
prerequisite for HLA recognition, due to major steric clashes with
P5-Pro and P6-His of the NY-ESO-160–72 peptide. The remo-
delling suggests that the structural plasticity of extended epitopes
can be accommodated to some extent by complementary remo-
delling of the TCR, but at an energetic cost, as illustrated by the
reduced KD of the KFJ5 TCR.
Discussion
A generic tenet of T-cell-mediated immunity is the ability of the
TCR to mould around a given HLA-I molecule when presenting a
peptide of canonical length1,46,49. However, our understanding of
TCR recognition towards extended HLA-I restricted peptides is
unclear despite their growing importance in T-cell-mediated
immunity6. Two contrasting TCR recognition modes have been
described for such extended peptides. Firstly, a TCR was observed
to perch atop a rigid and super-bulged 13-amino-acid peptide,
thereby making limited contacts with the HLA-I molecule12,16.
This same epitope was recognised differently by a distinct TCR,
but the epitope retained its rigid conformation16. Secondly, a
TCR ﬂattened a bulged peptide upon recognition to enable a
more conventional HLA-I centric footprint13. We describe a
polyclonal CD8+ T cell response to HLA-B*07:02 presenting the
immunodominant NY-ESO-160–72 peptide, which was detected in
patients with melanomas expressing NY-ESO-117, an antigen of
importance in onco-immunology given its tumour-dependent
expression and growing importance as a therapeutic
target39,43,50,51.
The structural basis for which distinct TCRs can recognise the
same pHLA-I complex has been described12,16,51–55. Two TCRs
(A6 and B7) bound Tax-HLA-A*02:01 in a largely conserved
docking mode despite differing TRAV gene usage52. Similarly
three TCRs (H27-14, T36-5 and C1-28)53 and two TCRs (DMF4
and DMF5)51, which utilised varied TRAV and TRBV gene
segments, recognised RFP-HLA-A*24:02 and MART-1-HLA-
A*02:01, respectively, with a conserved docking mode51,53. In
both cases the variation at the TCR–pHLA-I interface contributed
to altered interatomic contacts thereby providing a molecular
basis for differing TCR functional responses to pHLA-I stimu-
lation. In contrast, varied TCR gene usage directed against FLR-
HLA-B*08:01 resulted in differing docking topologies44,54,55.
Here, the RL42 TCR employed a central docking mode, whereas
the CF34 and LC13 TCRs docked towards the N-terminus and C-
terminus of the peptide, respectively44,54,55. Similar observations
have been observed for TCR recognition of HLA-B*35:08 pre-
senting an extended 13-amino-acid LPEP12,16.
Here we demonstrate a new mechanism of TCR recognition of
the same pMHC-I complex. Namely, we show how a polyclonal
TCR repertoire directed against the same pHLA-I complex can
either maintain or deform the conformation of the extended
epitope. The KFJ37-TCR bound NY-ESO-160–72-HLA-B*07:02
docking centrally atop the bulged central region of the peptide,
stabilising the dynamic central portion of the NY-ESO-160–72
peptide between the Vα and Vβ domains of the KFJ37-TCR.
Conversely the KFJ5-TCR adopted an alternate recognition
Table 2 Data collection and reﬁnement statistics
KFJ5 TCR NY-ESO-160–72-HLA-
B*07:02
KFJ5 TCR-NY-ESO-160–72-HLA-
B*07:02
KFJ37 TCR-NY-ESO-160–72-HLA-
B*07:02
Data collection
Temperature (K) 100 100 100 100
Space group P21 21 21 P21 21 21 P21 P1
Cell dimensions
a, b, c (Å) 49.90, 73.36, 123.04 50.19, 82.07, 112.05 64.36, 67.69, 105.72 74.41, 66.66, 96.28
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 102.93, 90 94.22, 97.88, 90
Resolution range (Å) 46.25–1.42 (1.49–1.42) 46.27–1.50 (1.58–1.50) 46.01–2.03 (2.14–2.03) 47.55–2.60 (2.74–2.60)
Rmerge 7.4 (48.7) 12.1 (56.4) 11.0 (57.9) 13.9 (68.3)
I/σ(I) 15.3 (3.8) 8.5 (2.9) 9.3 (2.5) 10.5 (2.2)
Completeness (%) 99.4 (97.8) 99.7 (100.0) 99.1 (96.8) 98.8 (98.2)
Redundancy 7.0 (6.8) 6.9 (7.2) 3.7 (3.7) 3.9 (3.9)
Total observations 603,854 (82,919) 517,968 (77,738) 211,802 (29,607) 217,862 (31,726)
Unique observations 86,034 (12,212) 74,669 (10,830) 57,083 (8094) 55,997 (8124)
Reﬁnement
Rworka(%) 19.8 21.1 20.4 19.3
Rfree (%) 21.8 23.0 25.6 24.8
No. of atoms
Protein 3448 3191 6580 13,197
Water 618 912 447 561
B-factors
Protein 27.2 19.6 40.8 39.5
Water 16.6 34.0 43.3 32.9
R.m.s. deviations
Bond lengths (Å) 0.007 0.005 0.006 0.004
Bond angles (°) 1.096 0.952 1.171 1.050
Values in parentheses are for the highest-resolution shell
a Rwork= Σhkl||Fo| – |Fc||/Σhkl|Fo| for all data excluding the 5% that comprised the Rfree used for cross-validation
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mode, whereby the bulged peptide was ﬂattened upon TCR
ligation. Although the identiﬁed NY-ESO-160–72-HLA-B*07:02
restricted T-cell population was characterised by a diverse TCR
gene repertoire, the KFJ37 and KFJ5-TCRs utilised the same
TRAV4*01 gene. In spite of differing peptide conformers being
recognised by alternate peptide docking modes there were some
vestiges of conserved pairwise56,57 germline contacts between the
TRAV4*01-encoded TCR α-chain and the HLA-B*07:02 mole-
cule and the peptide itself.
Our ternary structures highlighted the extent to which TCR
plasticity can be harnessed by the adaptive immune system to
evoke an immune response. Our ﬁndings provide novel insight
into the recognition of extended peptide epitopes via distinct T-
cell populations, and highlight their utilisation of widely differing
docking modes to recognise an oncogenic epitope of signiﬁcant
clinical interest.
KFJ37 TCR-NY-ESO-160–72-HLA-B*07:02
Vα
a b c
d e f
g h i
MHC-I
α1-helix
α2-helix
Vβ Vβ
Vβ
Vα Vα
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CDR2β
CDR2β
CDR2β
CDR2β CDR2β
CDR1β
CDR1β
CDR1β
CDR1β
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CDR3β
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CDR3β CDR3β CDR3β
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CDR2α
CDR2α
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CDR3α
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CDR3α
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KFJ5 TCR-NY-ESO-160–72-HLA-B*07:02 SB27 TCR-LPEP-HLA-B*35:08
Fig. 3 Overview of the ternary complexes. a KFJ37 TCR-NY-ESO-160–72-HLA-B*07:02, b KFJ5 TCR-NY-ESO-160–72-HLA-B*07:02 and c SB27 TCR-LPEP-
HLA-B*35:08 (PDB: 2AK4) with the TCR α- and β-chains coloured lighter and darker shades of blue, green and yellow, respectively. The HLA-B heavy chain
and β2-microglobulin molecules are shown as light and dark grey, respectively. Middle and lower panels show the TCR–HLA interfaces (d–f) and footprints
(g–i). The complementarity determining region (CDR) loops are coloured as follows; CDR1α light blue, CDR2α green, CDR3α teal, CDR1β orange, CDR2β
red, CDR3β yellow and framework (FW) contacts are coloured pink over the HLA-B*07:02 binding groove with the NY-ESO-160–72 peptide shown as black
sticks. The centre of mass of the respective Vα and Vβ domains are shown as grey and black spheres, respectively. In the lower panel the molecular surface
of the HLA-B molecules is shown with atomic contacts coloured according to the respective CDR-loop mediated interactions
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Methods
NY-ESO-160–72-HLA-B*07:02-speciﬁc CD8+ T-cell isolation. Patient peripheral
blood cells were obtained with informed consent and the study was approved by
the Human Research Ethics Committee of Austin Health (ethics approval number:
H2001-01256 and title: Immunological characterisation of patients with cancer)43.
PBMCs were isolated by density gradient centrifugation (Ficoll-Pague Plus, GE
Healthcare). Approximately 3 × 106 PBMCs from days 71, 197 and 547 post-NY-
ESO-1/ISCOMATRIX vaccination trial samples were pulsed with NY-ESO-155–72
peptide GPGGGAPRGPHGGAASGL (10 μg mL−1), for 1 h at 37 °C. The cells were
then cultured in a 24-well plate in 2 mL of RPMI-1640 (Gibco) containing 10% (v/
v) FCS (Thermo Trace), recombinant human IL-2 (25 UmL−1, Proleukin), Glu-
tamax (2 mM), benzylpenicillin (100 UmL−1), streptomycin (100 µg mL−1),
HEPES buffer (10 mM), 2-mercaptoethanol (50 µM), sodium pyruvate (1 mM) and
1 × nonessential amino acids (all from Gibco), harvested on days 12–15 for NY-
ESO-160–72-HLA-B*07:02 tetramer staining and ICS. ICS assay was performed by
stimulating CD8+ T cells with diluted synthetic peptide in 200 μL of complete
RPMI-1640 medium (described above) in 10 μg mL−1 Brefeldin A (BFA; Sigma-
Aldrich) and incubated for 5 h at 37 °C. Cells were stained with 50 μL of PBS-
diluted (1:50) antihuman CD3 and CD8 (BD Biosciences) for 30 min at 4 °C. The
monoclonal antibody target, clone name and source are presented in Supple-
mentary Table 3. Cells were washed once with 100 μL PBS and were resuspended in
100 μL 1% paraformaldehyde (PFA; EMS) for 20 min at room temperature. Cells
were washed once with PBS and stained with 50 μL of PBS-diluted (1:100) anti-
human IFN-γ (BD Biosciences) in 0.2% saponin (Sigma-Aldrich) for 30 min at 4 °
C. Cells were washed once with PBS, resuspended in 100 μL PBS and analysed
using FACSCanto II ﬂow cytometer (BD Biosciences). Data were processed with
FlowJo (Tree Star Inc.) software. NY-ESO-160–72-HLA-B*07:02 tetramer staining
was performed by staining cells with 100 μL of PBS-diluted (1:150) NY-ESO-160–72-
HLA-B*07:02 tetramer (0.44 mgmL−1) for 30 min at room temperature. Tetramers
were synthesised at the Tetramer Production Facility of the Ludwig Institute for
Cancer Research (LICR). Tetramer-stained cells (~2 × 106) were further stained
with antibodies speciﬁc to CD3 and CD8 (BD Biosciences). Tetramer and anti-
bodies were used at an empirically determined dilution factor with an optimum
signal to noise ratio. Tetramerhi, CD3hi and CD8hi cells were individually sorted
using FACSAria III ﬂow cytometer (BD Biosciences) into a round-bottom 96-well
plate containing 200 µL of complete RPMI-1640 medium (as described above but
without FCS) supplemented with 10% (v/v) heat-inactivated human AB sera
(LICR), 600 U recombinant human IL-2, phytohaemagglutinin (1 μg mL−1, Sigma-
Aldrich) and 3 × 105 healthy donors’ PBMCs (Australian Red Cross Blood Service).
PBMCs were mixed from three different donors in 1:1:1 ratio before being irra-
diated at 3000 rad using Gammacell 1000 Elite Irradiator 137Cs source (Nordion).
The gating strategy used to sort these cells is presented in Supplementary Fig. 6a.
Tetramer+ CD8+ clonal cells were further expanded on day 15 post cell-sorting for
another 10 to 12 days in the same setting as described above, with ~5000 clonal
cells transferred into each well on a round-bottom 96-well plate initially.
Characterising the CD8+ T-cell clone TCRβ repertoire. All NY-ESO-160–72-
HLA-B*07:02-speciﬁc CD8+ T-cell clones were stained with a panel of 24 anti-
bodies speciﬁc to TCR Vβ chains (Beckman Coulter) and analysed using FACS-
Canto II ﬂow cytometer (BD Biosciences), and data were processed with FlowJo
(Tree Star Inc.) software. The gating strategy used to analyse these cells is presented
in Supplementary Fig. 6b.
T cells recognise NY-ESO-160–72-HLA-B*07:02 on melanoma cells. SK-Mel-14,
an HLA-B*07:02+ melanoma line that expresses NY-ESO-1 antigen17 (Memorial
Sloan-Kettering Cancer Centre, USA), and LM-Mel-26, an HLA-B*07:02+ mela-
noma line that does not express NY-ESO-1 antigen17 (LICR), were treated with
recombinant human IFN-γ (50 ng mL−1, R&D Systems) for 48 h. CD8+ T-cell
clones were co-incubated with these melanoma lines in 1:2 ratio in 10 μg mL−1 of
Brefeldin A (BFA, Sigma-Aldrich) for 5 h followed by antibody staining for CD3,
CD4 and CD8 (BD Biosciences), and ICS. The gating strategy used to analyse these
cells is presented in Supplementary Fig. 6c. All cell lines were tested and/or treated
for mycoplasma and were mycoplasma free.
Peptide titration and alanine-scanning analyses. Serial log dilutions of NY-ESO-
160–72 and single alanine-substituted peptides at 1 μM down to 10−13 M in RPMI-
1640 medium were prepared. All peptides were synthesised with purity >95%
(Mimotopes, Australia). CD8+ T-cell clones were co-incubated with LM-Mel-26
(as APCs) in 1:2 ratio in serially diluted peptide and BFA (10 μg mL−1) for 5 h
followed by antibody staining and ICS (described above). The gating strategy used
to analyse these cells is presented in Supplementary Fig. 6c.
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Fig. 4 Molecular interactions at the TCR-NY-ESO-160–72–HLA-B*07:02 interface. a KFJ37 α-chain and b β-chain interactions with HLA-B*07:02 and NY-
ESO-160–72 shown as grey cartoon and black sticks, respectively. c Interaction between the KFJ37 TCR and the NY-ESO-160–72 peptide. Interaction between
the KFJ5 α-chain (d) and β-chain (e) with HLA-B*07:02. f Interaction between the KFJ5 TCR and the NY-ESO-160–72 peptide. The CDR loops are coloured
according to Fig. 3. Hydrogen, van der Waals and salt-bridge contacts are shown by black, yellow and red dashed lines, respectively
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Tetramer dissociation assay. CD8+ T-cell clones (~105) were stained with NY-
ESO-160–72-HLA-B*07:02 tetramer for an hour. Cells were then washed three times
with ‘cold buffer’ [PBS (Gibco) containing 0.5% (w/v) bovine serum albumin
(Gibco) and EDTA (2 mM, Sigma-Aldrich)] before being resuspended in RPMI-
1640 with 10% (v/v) FCS medium containing unconjugated anti-HLA-B7 (Ser-
otec), and were incubated at 37 oC. At designated time points (0, 5, 15, 30, 45, 60,
90, 120, 150, 180, 240 and 300 min), cells were harvested, washed for three times
with cold buffer and stained with anti-CD8 (BD Biosciences) before ﬂow cyto-
metric analysis. The gating strategy used to analyse these cells is presented in
Supplementary Fig. 6e.
CD8 co-receptor dependence assay. CD8 co-receptors on CD8+ T-cell clones
were blocked with unconjugated anti-CD8 (Serotec) for an hour. The treated CD8+
T-cell clones were incubated with or without P03-BLCL, an HLA-B*07:02+
Epstein-Barr virus transformed B-cell lymphoblastoid line (LICR) in 1:2 ratio in
serially diluted NY-ESO-160–72 peptide and BFA (10 μg mL−1) for 5 h, followed by
antibody staining and ICS (described above). Two other closely related assay
conditions were set up for the same CD8+ T-cell clones without anti-CD8
blocking. The gating strategy used to analyse these cells is presented in Supple-
mentary Fig. 6c.
TCR clonotyping and αβ TCR cell line generation. RNA was prepared from
CD8+ T-cell clones with Trizol (Invitrogen) and was reverse transcribed with
5′ rapid ampliﬁcation of cDNA end (RACE, Invitrogen) using gene-speciﬁc pri-
mers, Cα-GSP1 (GGGAAGAAGGTGTCTTCTGGAAT) and Cβ-GSP1
(GGCTGCTCAGGGCGTA). DNA fragments containing the sequence encoding
the CD8+ T-cell clone’s α- or β-chains were obtained by 5′ RACE PCR ampliﬁ-
cation of cDNA with combinations of the 5′ RACE abridged anchor (Invitrogen)
and gene-speciﬁc primers, Cα-GSP2 (GCTGTTGTTGAAGGCGTTTGC) or Cβ-
GSP2 (GTGGCCAGGCATACCAGTGT). Each PCR-derived α or β gene was
cloned into pGEM-T Easy vector (Promega) and sequenced. Five full-length genes
encoding TCR α- and β-chains (Table 1) separated by a hydrolase element P2A
linker58 were synthesised (GenScript) and subcloned into the pMIG expression
vector58. SKW3 cells, a TCR α/β−/− and derivative of KE-37 cells of acute lym-
phoblastic leukaemia (Leibniz Institute DSMZ-German Collection of Micro-
organisms and Cell Cultures) were transduced with vectors encoding the sequenced
αβ TCRs (Table 1, Supplementary Fig. 4) or the control LC13 TCR44. Retrovirus
transduction was performed by ﬁrst plating ~106 HEK 293 T cells in tissue culture
plate in 10 mL of complete DMEM medium containing 10% (v/v) FCS (Thermo
Trace), Glutamax (2 mM), benzylpenicillin (100 UmL−1), streptomycin (100 µg
mL−1), HEPES buffer (10 mM), 2-mercaptoethanol (50 µM), sodium pyruvate (1
mM) and 1 × nonessential amino acids (all from Gibco), and were incubated
overnight at 37 °C. 4 µg TCR 2A-linked/pMIG, 2 µg pVSV-G58 and 4 µg pPAME58
plasmids were dropwise added into a microtube containing 470 μL OptiMEM
medium (Invitrogen) and 30 μL Fugene 6 reagent (Roche), gently tapped to mix
and incubated at room temperature for 15 min. The mixture was dropwise added
to overnight-cultured HEK 293 T cells for plasmid co-transfection and further
incubated overnight at 37 °C. Cell culture medium of the overnight transfected
HEK 293 T cells was replaced with 10 mL of complete DMEM medium. About 105
SKW3 cells were seeded in tissue culture ﬂask in 10 mL of complete DMEM
medium and incubated overnight at 37 °C. After 12 h incubation, HEK 293 T-cell
culture medium containing retroviruses was carefully harvested and ﬁltered
through a 0.45 μm ﬁlter (Pall) to resuspend SKW3 cells and 10 μL polybrene (6 mg
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Fig. 5 Conformational plasticity of the NY-ESO-160–72 peptide dictates TCR recognition modes. a Side view of the NY-ESO-160–72 peptide as presented for
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mL−1, Sigma-Aldrich) was added to the resuspended cells. Ten millilitres of
complete DMEM medium was added to the HEK 293 T cells and incubated at
37 °C. This process was repeated for another six times in every 12 h interval.
Finally, TCR-transduced SKW3 cell culture medium was carefully aspirated, cells
were washed three times with PBS, resuspended in complete DMEM and further
incubated at 37 °C for 7–10 days. For T-cell activation assays, TCR-transduced
SKW3 cells (~105) were co-incubated with peptide-pulsed P03-BLCL cells (pre-
pulsed with 10−5 M NY-ESO-160–72 peptide for 2.5 h at 37 °C) in 1:1 ratio for 5 h at
37 °C. P03-BLCL cells without peptide pulsing were kept as a control. Cells were
then stained with antibodies speciﬁc to CD3 and CD69 (BD Biosciences), washed
once with PBS and subsequently ﬁxed in 1% (v/v) paraformaldehyde (EMS) before
ﬂow cytometric analysis. The gating strategy used to analyse these cells is presented
in Supplementary Fig. 6d.
Protein expression and puriﬁcation. Gene sequences encoding the functional
NY-ESO-160–72-HLA-B*07:02-speciﬁc TCR α- and β-chains were engineered with
the avidex disulphide linkage in the constant region (KFJ4 TCR: Thr159αCys,
Ser168βCys, Cys186βAla; KFJ5 TCR: Thr160αCys, Ser170βCys, Cys188βAla; KFJ15
TCR: Thr157αCys, Ser169βCys, Cys187βAla; KFJ37 TCR: Thr155αCys, Ser171β-
Cys, Cys189βAla), codon-optimised (GenScript) and subcloned into the pET-30
expression vector (Novagen). The KFJ4, KFJ5, KFJ15 and KFJ37 TCR heterodimers
were expressed as inclusion bodies in BL21 Escherichia coli and solubilised in 8 M
urea, 20 mM Tris–HCl pH 8, 0.5 mM EDTA and 1mM DTT. TCR heterodimers
were refolded by ﬂash dilution into 5M urea, 100 mM Tris–HCl pH 8.0, 2 mM
EDTA, 400 mM L-arginine-HCl, 0.5 mM oxidised glutathione and 5 mM reduced
glutathione before dialysis into 10 mM Tris–HCl pH 8.0 and puriﬁed by gel ﬁl-
tration and anion-exchange chromatography46. Soluble HLA-B*07:02 hetero-
dimers complexed to NY-ESO-160–72 were produced by expressing a truncated
form of the HLA-B*07:02 heavy chain and human β2m as inclusion bodies and
puriﬁed after oxidative refolding by gel ﬁltration and anion-exchange chromato-
graphy17. Conformational integrity of the puriﬁed TCRs and NY-ESO-160–72-HLA-
B*07:02 proteins was assessed using the conformationally sensitive monoclonal
antibodies 12H8 and W6/32, respectively46.
SPR. SPR experiments were conducted at 20 °C on a BIAcore 3000 instrument in
10 mM HEPES, pH 7.4, 150 mM NaCl supplemented with 0.005% (v/v) surfactant
P20 and 1% BSA. The analyte was captured on a CM5 sensorchip using the
conformational monoclonal antibody 12H859, whereby amine-coupled 12H8 was
used to immobilise the KFJ4, KFJ5, KFJ15 and KFJ37 TCRs to a surface density of
~300–350 response units. Serial dilutions from 200 to 0 µM of NY-ESO-160–72-
HLA-B*07:02 were injected over the immobilised TCR. The antibody surface was
regenerated with Actisep (Sterogene) between two injections. All experiments were
performed in duplicate with the kinetic parameters calculated using the BIAeva-
luation program using 1:1 Langmuir binding models with the addition of a drifting
baseline parameter.
Crystallisation and structure determination. All crystals were grown by the
hanging-drop, vapour-diffusion method at 20 °C, crystals were ﬂash-frozen in
mother liquor supplemented with 30% (w/v) of the respective PEG, and data were
collected at the Australian Synchrotron MX1 and MX2 beamlines, Melbourne.
Data were processed with the program XDS60 and were scaled with the SCALA
program of the CCP4 suite61. Orthorhombic crystals of the KFJ5 TCR were grown
in 0.1 M Tris–HCl pH 8.5 and 25% (w/v) PEG 3350 in 1:1 mixture with 8 mgmL−1
protein. KFJ5 TCR crystals belonged to the P212121 space group and diffracted to
1.4 Å. Molecular replacement was conducted with the TRBV28+ TCR HA1.7 (PDB
code 1J8H)62 as the search ensemble. An initial run of rigid body reﬁnement was
performed using the Phenix REFINE software63, the CDR loops of the TCR were
built in COOT64. Iterative rounds of reﬁnement cycles lead to a ﬁnal model with an
Rwork and Rfree of 19.8% and 21.8%, respectively. Orthorhombic crystals of the NY-
ESO-160–72-HLA-B*07:02 complex were grown in 0.2 M NaCl and 20% (w/v) PEG
3350 at a 1:1 mixture with 5 mgmL−1 protein. The NY-ESO-160–72-HLA-B*07:02
crystals belonged to the P212121 space group and diffracted to 1.5 Å. Molecular
replacement was conducted with RFL9-HLA-B*07:02 (PDB code 5eo0)48 as the
search ensemble. An initial run of rigid body reﬁnement was performed using
Phenix REFINE63 to ﬁnd optimal placement of the HLA-B*07:02 and β2m.
Iterative rounds of reﬁnement cycles lead to a ﬁnal model with an Rwork and Rfree of
21.1% and 23.0%, respectively. Triclinic crystals of the KFJ37 TCR-NY-ESO-160–72-
HLA-B*07:02 and monoclinic crystals of the KFJ5 TCR-NY-ESO-160–72–HLA-
B*07:02 complexes were grown in 0.1 M MIB pH 7 and 25% (w/v) PEG 1500, and
0.1 M BTP pH 8.8, 0.2 M Na-Iodide, 14% (w/v) PEG 3350 and 2% (w/v) PEG
20,000, respectively, at a 1:1 mixture with 10 mgmL−1 protein. The KFJ37 TCR-
NY-ESO-160–72-HLA-B*07:02 and KFJ5 TCR-NY-ESO-160–72–HLA-B*07:02
complexes belonged to the P1 and P21 spacegroups, and diffracted to 2.6 and 2.0 Å,
respectively. Molecular replacement was conducted with the reﬁned structures of
the KFJ5 TCR and NY-ESO-160–72-HLA-B*07:02 serving as separate search
ensembles. The electron density at the interface was clear and unambiguous. Initial
rounds of rigid body reﬁnement were performed using Phenix REFINE63. The
CDR loops of the respective TCRs were built in COOT64, where iterative rounds of
reﬁnement cycles lead to ﬁnal models with an Rwork and Rfree of 19.3 and 24.3% for
the KFJ37 TCR-NY-ESO-160–72–HLA-B*07:02 complex and 20.4 and 25.6% for the
KFJ5 TCR-NY-ESO-160–72–HLA-B*07:02 complex. Atomic contacts were deter-
mined with the CONTACT program from the CCP4i suite61. The quality of all
structures was conﬁrmed at the Research Collaboratory for Structural Bioinfor-
matics Protein Data Bank Data Validation and Deposition Services website. All
presentations of molecular graphics were created with the PyMOL molecular
visualisation system (The PyMOL Molecular Graphics System, Version 1.5.0.4
Schrödinger, LLC.
Data availability. The reﬁned coordinate and structure factors ﬁles for the X-ray
crystal structures of the NY-ESO-160–72-HLA-B*07:02, KFJ5 TCR, KFJ37 TCR-NY-
ESO-160–72-HLA-B*07:02 and KFJ5 TCR-NY-ESO-160–72-HLA-B*07:02 structures
have been validated using the Protein Data Base validation site and the coordinates
relating to the data reported in this study were deposited in the protein data bank
with identiﬁcation codes 6AT5, 6AT6, 6AVG, 6AVF, respectively. All remaining
data are available within the article and its Supplementary Information ﬁles and
from the corresponding authors on reasonable request.
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